04 December 2017 Written by  BioWorld

Semma raises $114M to advance cell therapy for diabetes

Semma Therapeutics Inc. has raised $114 million in a series B financing aimed at carrying its stem cell-derived beta cells, a potential therapy for people living with type 1 diabetes, through proof-of-concept studies. The company is preparing to file an investigational new drug (IND) application for the program while also exploring additional applications for its technologies.

Read the full article from BioWorld (HERE)